Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
JPMorgan Upgrades Novavax (NVAX) to Neutral, 'Sanofi Licensing Deal Brings In Flu Heavy Weight and Lifts Going Concern'
May 10, 2024 9:27 AM EDTJPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Underweight to Neutral.
The analyst comments "On the back of the announced licensing deal with Sanofi, we are upgrading Novavax shares to Neutral from Underweight. With the injection of cash upfront ($500M) removing Novavaxs going concern, , and the greater commercial heft brought to both COVID... More
Novavax (NVAX) stock soars 120% as Sanofi deal 'kicks off a new chapter'
May 10, 2024 4:15 AM EDT(Updated - May 10, 2024 9:20 AM EDT)
Novavax (NASDAQ: NVAX) shares skyrocketed more than 120% in premarket trading Friday, driven by the companys fiscal Q1 2024 report and more importantly, a vital, multi-billion dollar deal with French pharma giant Sanofi SA.
For the first quarter, Novavax reported a first-quarter loss per share of $1.05, wider than the $0.92 anticipated by analysts. The company's revenue was $93.85 million, significantly falling short of the consensus estimate of $141.16 million.
Novavax also offered revenue guidance for the fiscal 2024, expecting between $800 million and $1 billion, compared to the consensus estimate of $845.5... More
